NCT05077449View on ClinicalTrials.gov

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

February 22, 2024

Study Completion Date

November 30, 2029

Conditions
Advanced Breast Cancer
Interventions
DRUG

XZP-3287+Fulvestrant

XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease

DRUG

Placebo + Fulvestrant

Placebo 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease

Trial Locations (1)

100025

Chinese Academy of Medical Science, Beijing

All Listed Sponsors
lead

Xuanzhu Biopharmaceutical Co., Ltd.

INDUSTRY